W Pfützner1, J Pickert2, C Möbs2. 1. Klinik für Dermatologie und Allergologie, Allergie Zentrum Hessen, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldinger Str., 35043, Marburg, Deutschland. wpfuetzn@med.uni-marburg.de. 2. Klinik für Dermatologie und Allergologie, Allergie Zentrum Hessen, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldinger Str., 35043, Marburg, Deutschland.
Abstract
BACKGROUND: Personalized medicine offers new perspectives for diagnostic measurements and medical treatment, but also puts greater demands on the physician. OBJECTIVES: Developments, potentials and potential pitfalls of personalized medicine in allergology. METHODS: Overview, evaluation and discussion of the current state of science on the basis of selected examples. RESULTS: Allergic diseases like allergic rhinitis, atopic eczema or anaphylaxis can be classified into various clinical phenotypes, which are based on different immunological endotypes. These can be captured and categorized by a wide variety of omics technologies. The identification of endotype specific biomarkers holds promising opportunities of more precise diagnostics, the implementation of novel targeted therapies or the development of optimized preventive strategies. However, individualized analysis and assessment of the significance of the measurements represent special challenges. CONCLUSIONS: Findings of the complex omics technologies need to be evaluated by comprehensive prospective studies in order to validate their clinical relevance and suitability for personalized medicine in allergology.
BACKGROUND: Personalized medicine offers new perspectives for diagnostic measurements and medical treatment, but also puts greater demands on the physician. OBJECTIVES: Developments, potentials and potential pitfalls of personalized medicine in allergology. METHODS: Overview, evaluation and discussion of the current state of science on the basis of selected examples. RESULTS:Allergic diseases like allergic rhinitis, atopic eczema or anaphylaxis can be classified into various clinical phenotypes, which are based on different immunological endotypes. These can be captured and categorized by a wide variety of omics technologies. The identification of endotype specific biomarkers holds promising opportunities of more precise diagnostics, the implementation of novel targeted therapies or the development of optimized preventive strategies. However, individualized analysis and assessment of the significance of the measurements represent special challenges. CONCLUSIONS: Findings of the complex omics technologies need to be evaluated by comprehensive prospective studies in order to validate their clinical relevance and suitability for personalized medicine in allergology.
Authors: G Passalacqua; G Melioli; F Bonifazi; S Bonini; E Maggi; G Senna; M Triggiani; E Nettis; R E Rossi; A Vacca; G W Canonica Journal: Allergy Date: 2013-07-29 Impact factor: 13.146
Authors: F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Vesselin Dimov; Motohiro Ebisawa; Yehia M El-Gamal; Dennis K Ledford; Richard F Lockey; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong; Margitta Worm Journal: Curr Opin Allergy Clin Immunol Date: 2012-08
Authors: R Valenta; M Duchene; S Vrtala; T Birkner; C Ebner; R Hirschwehr; M Breitenbach; H Rumpold; O Scheiner; D Kraft Journal: J Allergy Clin Immunol Date: 1991-12 Impact factor: 10.793